Close
Help




JOURNAL

Biomarkers in Cancer

PET Metabolic Biomarkers for Cancer

Submit a Paper


Biomarkers in Cancer 2016:Suppl. 2 61-69

Review

Published on 20 Sep 2016

DOI: 10.4137/BIC.S27483


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract

The body’s main fuel sources are fats, carbohydrates (glucose), proteins, and ketone bodies. It is well known that an important hallmark of cancer cells is the overconsumption of glucose. Positron emission tomography (PET) imaging using the glucose analog 18F-fluorodeoxyglucose (18F-FDG) has been a powerful cancer diagnostic tool for many decades. Apart from surgery, chemotherapy and radiotherapy represent the two main domains for cancer therapy, targeting tumor proliferation, cell division, and DNA replication—all processes that require a large amount of energy. Currently, in vivo clinical imaging of metabolism is performed almost exclusively using PET radiotracers that assess oxygen consumption and mechanisms of energy substrate consumption. This paper reviews the utility of PET imaging biomarkers for the detection of cancer proliferation, vascularization, metabolism, treatment response, and follow-up after radiation therapy, chemotherapy, and chemotherapy-related side effects.



Downloads

PDF  (1.07 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




Quick Links


New article and journal news notification services